Every 8-K that Assembly Biosciences, Inc (ASMB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ASMB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ASMB filings page.
Assembly Biosciences, Inc. filed an amended current report to correct an administrative tagging error, clarifying that its August 13, 2026 submission relates to results of operations and financial condition. The underlying second-quarter 2026 information remains unchanged.
For the quarter ended June 30, 2026, collaboration revenue from Gilead rose to $13.4 million, while research and development expense declined to $14.9 million and general and administrative expense was $4.8 million. Net loss narrowed to $3.9 million, or $0.20 per share. Cash, cash equivalents and marketable securities totaled $320.4 million, supported by a recently completed $115 million gross financing and a collaboration extension payment from Gilead that together are projected to fund operations into 2029.
Operationally, Assembly expanded ABI-6250 into cholestatic liver diseases with Phase 2 studies in hepatitis delta virus and cholestatic indications planned between late 2026 and early 2027. In its partnered herpes program, GS-1179 was selected to advance, with a Phase 2 trial in recurrent genital herpes expected to start by year-end 2026 and a potential role alongside HIV PrEP under consideration.
Assembly Biosciences reported second quarter 2026 results and pipeline progress. Cash, cash equivalents and marketable securities were $320.4 million as of June 30, 2026, helped by a recently completed $115 million gross financing and collaboration funding from Gilead, and are projected to fund operations into 2029, including a $75 million Gilead extension payment expected in the fourth quarter of 2026.
Collaboration revenue from Gilead rose to $13.4 million from $9.6 million a year earlier, while research and development expenses declined to $14.9 million from $16.1 million. Net loss narrowed to $3.9 million, or $0.20 per share, compared with $10.2 million, or $1.33 per share, reflecting higher revenue, lower R&D and higher interest income.
Strategically, the company expanded ABI-6250 into cholestatic liver diseases with a Phase 2 study planned in early 2027 and plans Phase 2 trials in chronic HDV and cholestatic liver diseases by late 2026 and early 2027. Gilead selected GS-1179 (HSV helicase‑primase inhibitor) to move into Phase 2 by year-end 2026, with Assembly Biosciences evaluating whether to opt into a 40% U.S. cost‑profit share.
Assembly Biosciences, Inc. reported the results of its annual stockholder meeting held on June 4, 2026. Stockholders approved amendments to the company’s equity incentive and employee stock purchase plans, elected the full slate of director nominees, and ratified the independent auditor.
The amendment to the 2018 Stock Incentive Plan increases shares reserved for issuance from 1,478,333 to 2,678,333. The Employee Stock Purchase Plan reserve was increased from 225,000 to 515,000 shares. Stockholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers.
Assembly Biosciences, Inc. completed an underwritten public offering of common stock and pre-funded warrants, generating approximately $107.4 million in net proceeds after underwriting discounts, commissions and estimated expenses. Gross proceeds were about $115.0 million, providing significant additional funding for the company’s biotechnology programs.
The deal included 3,358,602 common shares at $26.50 per share, pre-funded warrants to purchase up to 415,000 shares at $26.499 per warrant, and 566,040 additional shares purchased in full by the underwriters via a 30-day option. Executive officers and directors agreed to 90-day lock-up arrangements, and the company plans to use the proceeds mainly to fund clinical development of its pipeline candidates and for general corporate purposes.
Assembly Biosciences is expanding development of its investigational oral drug ABI-6250 beyond chronic hepatitis delta virus into primary biliary cholangitis and primary sclerosing cholangitis, two autoimmune cholestatic liver diseases with significant unmet medical need, particularly PSC where no therapies are approved.
ABI-6250 is a small-molecule inhibitor of the NTCP receptor on liver cells, blocking bile acid uptake and HDV entry. The company has completed a Phase 1a trial in healthy participants, showing target engagement and dose-dependent increases in plasma bile acids, and completed chronic toxicology studies supporting longer-term dosing.
The company plans a Phase 2 study of ABI-6250 in HDV in the fourth quarter of 2026 and a Phase 2 basket study in cholestatic liver diseases focused on PBC and PSC in the first quarter of 2027, following a pre-IND discussion with the U.S. Food and Drug Administration.
Assembly Biosciences, Inc. reported first quarter 2026 results that show continued R&D investment alongside a manageable loss and solid cash position. Cash, cash equivalents and marketable securities totaled $226.6 million as of March 31, 2026, which the company believes can fund operations into 2028.
For the quarter, collaboration revenue from its Gilead partnership was $8.2 million, while research and development expenses were $14.9 million and general and administrative expenses were $4.7 million. Net loss attributable to common stockholders was $9.1 million, or $0.54 per share.
Operationally, the company completed Phase 1b studies for herpes candidates ABI-5366 and ABI-1179 and chronic toxicology studies for ABI-6250 in hepatitis delta virus. A Phase 2 study for ABI-6250 is expected to begin in the fourth quarter of 2026, and a decision on opting into a 40% U.S. cost-profit share with Gilead for the herpes program is planned by mid-2026.
Assembly Biosciences, Inc. has adopted a new 2026 Corporate Bonus Plan, effective January 1, 2026, to motivate, retain, attract and reward employees using performance-based cash bonuses for results achieved between January 1 and December 31 each year.
Bonuses will be based on Company-wide “Corporate Objectives” and individual or team “Individual Objectives,” with weightings that vary by level, from 100% corporate for the CEO to 25% corporate and 75% individual for associate director and below. Target bonus opportunities range up to 75% of base salary for the CEO, 30%–55% for other executives and up to 28% for non-executives, with actual payouts ranging from 0 to 1.5 times the target. The Compensation Committee also increased CEO Jason A. Okazaki’s bonus target from 60% to 65% of base salary for fiscal 2026.
Assembly Biosciences reported sharply improved 2025 results, driven by its virology collaboration with Gilead. Collaboration revenue rose to $72.3M from $28.5M, while net loss narrowed to $6.1M, or $0.55 per share, from $40.2M in 2024.
Cash, cash equivalents and marketable securities increased to $248.1M as of December 31, 2025, supporting operations into 2028. The company received a net $35M option fee as Gilead licensed its helicase-primase inhibitor program, though Gilead declined its option on HBV candidate ABI‑4334. Assembly plans a potential U.S. cost-profit share election on the herpes program by mid‑2026 and aims to start Phase 2 for HDV candidate ABI‑6250 by the end of 2026.
Assembly Biosciences, Inc. filed a current report to share that it has released its financial results for the quarter ended September 30, 2025. On November 10, 2025, the company issued a press release describing these quarterly results, which is included with the report as Exhibit 99.1. The company notes that this press release is being furnished under the results of operations and financial condition disclosure rules, rather than being formally filed under those provisions.
Assembly Biosciences completed a registered underwritten offering and a concurrent private placement to raise capital. The registered offering included 5,591,840 shares of common stock at an offering price of $19.60 per share plus accompanying Class A and Class B warrants, and pre-funded warrants to purchase up to 1,040,820 shares at $19.599 per pre-funded warrant. The closing of the Offering occurred on August 11, 2025, and the aggregate net proceeds to the Company from the Offering were approximately $122.0 million, after estimated offering expenses.
Concurrently, the Company sold 2,295,920 shares and accompanying warrants to Gilead Sciences in a private placement, with aggregate net proceeds of approximately $45.0 million. The Company intends to use the net proceeds from the Offering and the Private Placement for general corporate purposes. Key warrant terms disclosed include a $21.60 exercise price for the Warrants, Class A Warrants becoming immediately exercisable and expiring no later than August 11, 2030, Class B Warrants exercisable after November 15, 2026 and expiring December 31, 2026, and Pre-Funded Warrants with an initial exercise price of $0.001 and no termination date.
Assembly Biosciences (ASMB) filed an 8-K reporting interim Phase 1b results for its long-acting HSV helicase-primase inhibitor ABI-5366.
The 350 mg once-weekly oral dose achieved a 94% reduction in HSV-2 viral shedding versus placebo (p<0.01) over 29 days, exceeding the study’s 80-85% target. Secondary endpoints also improved: 94% lower genital-lesion rate and 98% reduction in high-viral-load samples (p<0.05). The drug was well-tolerated at doses up to 350 mg weekly, and its pharmacokinetic profile supports both once-weekly and potential once-monthly dosing.
With these data, Assembly plans to move directly into Phase 2 preparations while finishing the Phase 1b trial’s monthly-dosing cohort. Chronic toxicology studies are complete and expected to support longer-term dosing in Phase 2.